Toll Free Helpline (India): 1800 1234 070

Rest of World: +91-9810852116

NAAS RATING: 5.23 | Free Publication Certificate
NAAS Rating: 5.23 new

Vol. 6, Issue 3 (2017)

Usage the preparation of ribonucleic acid (Nuklex) in therapy of hepatitis C

Kondryn OYe, Vaskul NV and Virstiuk NH
Ukraine belongs to regions with high population infected by virus HC. Among the latest trends, HC treatment search find drugs can modulate inflammatory responses and antiviral innate immunity to fight viral infections. The aim of this study is to examine the effectiveness of the drug Nuklex in the treatment of patients with HC and the optimal therapeutic dose. It was determined that usage of Nuklex for treatment of hepatitis C is accompanied by a rapid disappearance of the main clinical symptoms, improvement of health in the patients, supports normalization of cytolytic liver function in patients with minimal or moderate activity hepatitis. The isolate usage of Nuklex as the only antiviral drug for hepatitis C patients with low initial viral load HCV (<800,000 IU / ml) in a daily dose of 1.5 g.
Pages: 164-167  |  1263 Views  55 Downloads

The Pharma Innovation Journal
How to cite this article:
Kondryn OYe, Vaskul NV, Virstiuk NH. Usage the preparation of ribonucleic acid (Nuklex) in therapy of hepatitis C. Pharma Innovation 2017;6(3):164-167.
Important Publications Links
The Pharma Innovation Journal

The Pharma Innovation Journal

Call for book chapter
The Pharma Innovation Journal